Applications
Application Search for UHPLC & HPLC
| Classification | Data name | Compound name | Product code | Column | |
| Antibodies, Antibody-Drug-Conjugates | Human IgM (κ), myeloma protein | Normal human IgM (κ), myeloma protein | DL30S05-5008WT | YMC-Pack Diol-300 | |
| Antibodies, Antibody-Drug-Conjugates | Human immunoglobulins | Human IgM (κ), myeloma protein Normal human IgA | DL30S05-5008WT | YMC-Pack Diol-300 | |
| Antibodies, Antibody-Drug-Conjugates | Human immunoglobulins | Human IgM (κ), myeloma protein Normal human IgG | DL30S05-5008WT | YMC-Pack Diol-300 | |
| Antibodies, Antibody-Drug-Conjugates | Human immunoglobulins | Human IgM (κ), myeloma protein Normal human IgA Normal human IgG | DL30S05-5008WT | YMC-Pack Diol-300 | |
| Antibodies, Antibody-Drug-Conjugates | Human immunoglobulins | Human IgM (κ), myeloma protein Normal human IgA Normal human IgG | DL20S05-5008WT | YMC-Pack Diol-200 | |
| Antibodies, Antibody-Drug-Conjugates | Analysis of Bevacizumab (Avastin®) by SEC-MALLS | Bevacizumab (Avastin®) | DLM25S03-3046WT | YMC-SEC MAB | |
| Antibodies, Antibody-Drug-Conjugates | Analysis of oxidised monoclonal antibodies using BioPro HIC BF | NISTmAb (oxidised) | BHB00S04-1046WT | BioPro HIC BF | |
| Antibodies, Antibody-Drug-Conjugates | MS compatible charge variant analysis of 28 commercial monoclonal antibodies by CEX | Eculizumab Panitumumab Emicizumab Reslizumab Infliximab Pembrolizumab Natalizumab Elotuzumab Nivolumab Ixekizumab Bevacizumab Benralizumab Atezolizumab Obinutuzumab Cetuximab Denosumab Daratumumab Dalotuzumab Pertuzumab Ramucirumab Trastuzumab Ipilimumab NISTmab Palivizumab Rituximab Belimumab Adalimumab Ofatumumab | SF00S05-1046WP | BioPro IEX SF | |
| Antibodies, Antibody-Drug-Conjugates | Native online SCX-MS analysis of monoclonal antibodies | NISTmAb | SF00S05-1046WP | BioPro IEX SF | |
| Antibodies, Antibody-Drug-Conjugates | Online native HIC-MS analysis of cys-linked ADCs | SigmaMAb ADC-mimic | BHB00S04-1046WT | BioPro HIC BF | |
| Antibodies, Antibody-Drug-Conjugates | Online native HIC-MS analysis of monoclonal antibodies and their molecular variants | mAb mixture (9 in-house mAbs) | BHB00S04-1046WT | BioPro HIC BF | |
| Antibodies, Antibody-Drug-Conjugates | Separation of the ADC Brentuximab vedotin from ist aggregates and fragments | Brentuximab vedotin | DLM25S03-3046WT | YMC-SEC MAB | |
| Antibodies, Antibody-Drug-Conjugates | Monoclonal antibody (MAb) | Mouse monoclonal IgG1 (anti-human IgG4) | SF00S05-1046WP | BioPro IEX SF | |
| Antibodies, Antibody-Drug-Conjugates | Monoclonal antibody (MAb) | Humanized monoclonal IgG1 | SF00S05-1046WP | BioPro IEX SF | |
| Antibodies, Antibody-Drug-Conjugates | Native AEX-MS analysis of IgG4-based mAbs | IgG4-based mAbs (6 in-house mAbs) | QF00S05-1046WP | BioPro IEX QF | |
| Antibodies, Antibody-Drug-Conjugates | Charge heterogeneity characterisation of an IgG4-based mAb using AEX coupled to MS | Inhouse IgG4-based mAb | QF00S05-1046WP | BioPro IEX QF | |
| Antibodies, Antibody-Drug-Conjugates | High recoveries from IEX analysis of mAbs with the first injection without preconditioning | Bevacizumab (Avastin®) | SF00S05-1046PTC | YMC Accura BioPro IEX SF | |
| Antibodies, Antibody-Drug-Conjugates | DAR determination of a 3rd generation, site-specific ADC using reversed phase chromatography | Site-specific, 3rd generation ADC (in-house ADC) | TB30S03-1546PTH | YMC-Triart Bio C4 | |
| Antibodies, Antibody-Drug-Conjugates | IEX of Brentuximab vedotin injection solution using MS-compatible conditions | Brentuximab vedotin | SF00S03-10Q1PTC | YMC Accura BioPro IEX SF | |
| Antibodies, Antibody-Drug-Conjugates | IEX of Brentuximab vedotin injection solution using MES buffer | Brentuximab vedotin | SF00S03-1046PTC | YMC Accura BioPro IEX SF |
 by YMC-SEC-MAB and MALLS/images/Analysis of Bevacizumab (Avastin) by YMC-SEC-MAB and MALLS.png){kind=link}
/images/AK240328C_Brentuximab_vedotin(IEX_LCMS).png){kind=link}
/images/C240226B_Brentuximab_vedotin_(IEX_MES).png){kind=link}